News

Obesity, smoking, and poor sleep raise risk of myeloma precursor

Obesity, a history of heavy smoking, and limited sleep are risk factors for developing monoclonal gammopathy of undetermined significance (MGUS), a precursor condition to multiple myeloma, a large U.S. study shows. These findings will help inform future work to identify groups who “may benefit from targeted screening strategies, enhanced…

Darzalex Faspro combo benefits patients new to MM and transplant

Adding Darzalex Faspro (daratumumab and hyaluronidase) — a subcutaneous or under-the-skin formulation of Darzalex (daratumumab) — to a standard combination therapy regimen led to significantly better outcomes for people who are newly diagnosed with multiple myeloma and transplant eligible. That’s according to four-year data from the Phase 3…

FDA delays its decision on earlier Abecma treatment for RRMM

The U.S. Food and Drug Administration (FDA) is delaying its review of an application that seeks to allow the cell therapy Abecma (idecabtagene vicleucel) to be used earlier in the treatment of difficult-to-manage multiple myeloma. Abecma currently is FDA-approved for adults with relapsed or refractory multiple myeloma (RRMM) who…

Foundation awards $21M in grants for multicenter myeloma research

Three research projects have been awarded $7 million each from the Multiple Myeloma Research Foundation (MMRF) to develop more effective treatment options for newly diagnosed high-risk multiple myeloma and smoldering multiple myeloma. Smoldering multiple myeloma is an early, slow-growing blood cancer that can develop into active multiple…